AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00646854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab
Description: Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
Study NCT00646854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
Description: 6 cycles of CHOP every 2 weeks
Study NCT01956344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
Study NCT01332799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol or placebo
Description: Daily active drug (allopurinol administered orally) administered orally for 3 years.
Study NCT01332799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill administered orally for 3 years.
Study NCT05873907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection
Study NCT05873907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as SC injection
Study NCT03223168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hayek RTX ventilator
Description: Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
Study NCT00575341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone
Description: 25 mg DHEA, oral, once daily
Study NCT00575341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral, once daily
Study NCT00118456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEE788
Study NCT03141294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reformative dilation technique
Description: reformative dilation technique was used when operating tracheostomy
Study NCT03141294 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: reformative dilation technique
Description: reformative dilation technique was used when operating tracheostomy
Study NCT04229732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearMateTM
Description: Passive isocapnic hyperventilation breathing circuit.
Study NCT04193514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The intervention is a 7-day self-guided acceptance-based intervention using a published Acceptance and Commitment Therapy self-help work book. This therapy is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of depression, anxiety and/or stress. The therapy includes two components: (a) educating patients about the exacerbation of stress and negative affect through rigid attempts at experiential avoidance, and (b) introducing acceptance and the willingness to experience pregnancy-related sensations and cognitions as an alternative to experiential control, through the practice of intentional and non-judgmental paying attention to one's thoughts, feelings, images and bodily sensations (including aversive symptoms) and learning to see thoughts as an ongoing process distinct from self rather than merely an event with literal meaning.
Study NCT05925543 — intervention group
Intervention type: PROCEDURE
Intervention: Kasai portoenterostomy operation.
Description: Kasai portoenterostomy operation for biliary atresia patients.
Study NCT02224885 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CT-guided percutaneous biopsy or ablation
Description: Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
Study NCT00377390 — intervention group
Intervention type: BIOLOGICAL
Intervention: Omalizumab
Description: Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
Study NCT05354648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxic-hyperoxic preconditioning
Description: Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia. HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, then a period of breathing with atmospheric air (normoxia and normocapnia) until the cardio-pulmonary bypass is connected.
Study NCT05354648 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia until the cardio-pulmonary bypass is connected.
Study NCT04016532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Personalized dietary management at home
Description: Personalized dietary management at home to improve nutritional status.~* Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs \& Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~* There will be no change in medical prescriptions
Study NCT03663478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour
Study NCT03663478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
Study NCT01257009 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide
Description: 0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled carbon monoxide
Description: 0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled carbon monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide
Description: 3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled carbon monoxide
Description: 3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: 3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Carbon Monoxide
Description: 3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
Study NCT00531856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Carbon Monoxide
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
Study NCT03460951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cervical MRI
Description: Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
Study NCT02127281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena
Description: Device will be applied at end of procedure over closed incision.
Study NCT02552342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study NCT02552342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01095692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Organ Prolapse and Suburethral TOT implantation
Description: Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
Study NCT01095692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Organ Prolapse intervention
Description: Procedure/Surgery: Pelvic Organ Prolapse intervention
Study NCT02148484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Adolescents
Study NCT02148484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Client Centered Therapy
Study NCT04047147 — intervention group
Intervention type: OTHER
Intervention: Enrollment in the Million Hearts CVD Risk Reduction Model
Description: The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~* Risk stratify eligible Medicare FFS beneficiaries~* Provide CVD care management to high-risk beneficiaries~* Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries.
Study NCT04047147 — intervention group
Intervention type: OTHER
Intervention: Enrollment in control provider organizations
Description: Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
Study NCT03850639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based exposure therapy
Description: The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
Study NCT03955237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: dextrose containing infusion
Description: Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
Study NCT01123265 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
Study NCT03775538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions
Study NCT03775538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device
Study NCT01123265 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF
Description: Anti-TNF to be administered per standard of care within the practice.
Study NCT00060307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00060307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01336660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine F(ab')2 antivenom
Description: A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
Study NCT01336660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intensive care support plus placebo
Description: Intensive care support as needed plus placebo
Study NCT03815669 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic subacromial decompression
Description: Arthroscopic subacromial decompression
Study NCT03538405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting cushions
Description: Cushions were placed in a way that the head and four limbs were well supported, without leaving empty space between body and cushions or mattress.
Study NCT03538405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmonic techniques
Description: Harmonic techniques (HT) is a group of manual techniques described by Lederman (2000).The goal of this techniques in this study was to reduce the muscle tone and additionally/subsequently increase the ROM.
Study NCT03904966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
Study NCT03904966 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio tape
Description: Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
Study NCT03904966 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
Study NCT03904966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
Study NCT00977847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Portals for collecting Family History data
Description: Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
Study NCT01772667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Rehabilitation
Description: Rehabilitation program in Schoen Klinik Berchtesgadener Land
Study NCT03773302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Study NCT03773302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Study NCT03773302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Study NCT01799057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
Study NCT01799057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
Study NCT03706053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Midodrine Hydrochloride, enteral, 10 or 20 mg
Study NCT03706053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: investigational pharmacy formulated placebo comparator
Study NCT01885780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted Astigmatic keratotomy
Description: Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
Study NCT03705416 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy
Description: endoscopic suturing of stomach
Study NCT03705416 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
Study NCT01670266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Study NCT01670266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01670266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03904966 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
Study NCT01854008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation more the urban circuit
Description: included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
Study NCT01854008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation program but not given urbane circuits
Description: Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
Study NCT00985257 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DIDGET (Investigational Blood Glucose Monitoring System)
Description: Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
Study NCT01515826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)
Description: One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
Study NCT01515826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
Description: One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
Study NCT03963063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Description: Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~* individualized optimised stroke volume by mini-fluid challenge first~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg~* keep cardiac index ≧ 2.5 L/min/cm2
Study NCT03963063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non goal-directed fluid therapy
Description: Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg
Study NCT01887145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
Study NCT01887145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.